Home > Author

Blog Posts by Author: XIFIN

The 5 Keys to Minimizing the Impact of PAMA

At this year's Executive War College Conference, XIFIN CEO and Executive Chairman, Lâle White presented on PAMA’s effects on laboratories and gave some thought-provoking ideas on how labs can respond. This blog post will cover many of the topics that Lâle discussed, starting with this timeline of industry events which provides background on the laboratory reimbursement environment...

Read


Accurate Patient Responsibility Estimates Dramatically Improve the Patient Experience

Customer experience is one of the most significant long-term differentiators in healthcare and diagnostics, as it is in virtually all other sectors. There is a direct correlation between customer experience and engagement, and consumers have been trained to expect more when it comes to service and experience by companies such as Amazon, Apple, and Southwest Airlines. A survey of 1,000 patients...

Read


Laboratory Economics' Anatomic Pathology & Clinical Lab Survey

Attention pathology groups! Laboratory Economics, an independent market research firm focused on the business of pathology and laboratory medicine, is conducting a survey to gain insight on current business trends among anatomic pathology groups and clinical labs. Please take a few moments to fill out this survey and in return for your participation, you will receive a full summary of the survey...

Read


Final Steps in Preparing for the PAMA Reporting Period (Part 2)

In our last post of this series, we identified “The First Steps in Preparing for the PAMA Reporting Period” as confirming your laboratory’s applicable lab status, executing an RCM data review, and assigning a project team and project team lead. Once you have carried out these steps, there are four additional steps to be taken before you complete your submission.  Step 4:...

Read


The First Steps in Preparing for the PAMA Reporting Period (Part 1)

Solid reporting from all applicable laboratories is the key to mitigate future PAMA fee schedule cuts. This means labs need to be able to report on actual allowables vs. payments, validate the accuracy of payments, and optimize appeals activity to avoid under-reporting payments. All applicable labs are included in the current data collection period now underway for the first half of 2019.Step 1:...

Read


EKRA‘s Real Impact on Clinical Laboratories

With the opioid epidemic becoming an increasingly serious issue in the United States, our government has responded with the Substance Use-Disorder Prevention that Promotes Opioid Recover and Treatment for Patients and Communities Act, also known as the Support Act. This act essentially aimed to reduce access to opioids. One of more than 70 bills in the Support Act is the Eliminating...

Read


What You Need to Know About the Changing Landscape and the Impact to How Labs Must Submit Claims to Enable Reimbursements

Prior authorization in the medical field is a necessary but flawed process that causes challenges for physicians as well as everyone involved from submission to approval. For those who are unaware, prior authorization is a requirement that a physician obtains approval from a patients health insurance plan to prescribe a specific medication or lab test. Prior authorization is a technique...

Read


How to Prepare Your Lab for Next-Gen Sequencing and Big Data Science

Industry experts estimate that anywhere between 100 million to 2 billion genomes will be sequenced by 2025. With the growing demand for next-generation sequencing (NGS), from bases to whole genomes, and the growing demand for sequence-based drug discovery applications and diagnostic testing, there’s no denying that labs will need to accommodate a huge amount of data very soon.What does genomics...

Read